Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review

The rapid development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations including but not limited to exon 19 deletions (19 del) and point mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lingling, Wang, Zhen, Du, Haiwei, Chen, Songan, Wang, Pingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059409/
https://www.ncbi.nlm.nih.gov/pubmed/33898306
http://dx.doi.org/10.3389/fonc.2021.605853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059409/
https://www.ncbi.nlm.nih.gov/pubmed/33898306
http://dx.doi.org/10.3389/fonc.2021.605853

Ejemplares similares